Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma

About this update from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H

CHENGDU, China, July 15, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) and Harbour BioMed (HKEX: 02142) today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for SKB575/HBM7575, a long-acting bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and an undisclosed target co-developed by the two parties, for the treatment of asthma . Previously, the first participant has been dosed in a Phase I clinical study of SKB575/HBM7575 for the treatment of atopic dermatitis. Asthma is a chronic respiratory condition affecting approximately 300 million people worldwide, with prevalence continuing to rise. Despite the availability of treatment options, many patients experience persistent symptoms, frequent exacerbations, and reduced quality of life. Current therapies - mainly inhaled corticosteroids (ICS) and bronchodilators - are inadequate for some patients, underscoring the urgent need for more effective, long-acting treatments that address the underlying disease mechanisms. Dr. Michael Ge, CEO of Kelun-Biotech, stated: "With the company's active efforts, SKB575/HBM7575 has initiated clinical trials for two chronic immune‑mediated diseases, atopic dermatitis and asthma. As a differentially designed and engineered bispecific antibody, SKB575/HBM7575 is expected to achieve potent inflammation control and broad patient coverage through its dual-target synergistic mechanism, whilst offering convenient administration. We will vigorously advance the development of this drug to fully realize its clinical value."  About SKB575/HBM7575 SKB575/HBM7575 is a long-acting bispecific antibody targeting TSLP and an undisclosed antigen, with a dual mechanism of action. On one hand, by blocking the interaction between TSLP and its receptor, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells. On the other hand, binding to and blocking the undisclosed target generates a synergistic effect, with the potential to achieve broader control of inflammation compared to single-target approaches. SKB575/HBM7575 has been engineered to allow for longer dosing intervals and a convenient subcutaneous route of administration. Based on preclinical half-life data, the anticipated human half-life is expected to support dosing intervals of more than three months, positioning it as a potential best-in-class therapy.

View stock analysis, news, and events for Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H